NCT05737706: A trial that was reported late by Mirati Therapeutics Inc.
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT05737706 |
|---|---|
| Title | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 20, 2023 |
| Completion date | Aug. 30, 2026 |
| Required reporting date | Aug. 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Jan. 17, 2025 |
| Days late | None |